Merkel Cell Carcinoma

🧬SKIN CANCER STUDY: @WeillCornell is now enrolling subjects in HCRN MCC20-443 "Phase II Study of PRRT with Immunotherapy for Patients with Merkel Cell Cancer (iPRRT)" @pashtoonkasi Learn more: https://t.co/kXM2vrmlVT (@hoosiercancer)

1. Basal cell carcinoma, adenoid type 2. Trichoepithelioma with gorgeous papillary mesenchymal bodies 3. Merkel cell carcinoma 4. Pilomatrixoma . (@FJMazorra)

Another milestone reached ✅ PGY-1 completed @UpstateIM_Res 🔜 Merkel Cell Carcinoma Clinical Research Fellow in Seattle, WA for @DermatologyUW & @PaulNghiem (@AustinJabbour)

Shailender Bhatia, MD, on Merkel Cell Carcinoma: Results From CheckMate 358 on Nivolumab With or Without Ipilimumab https://t.co/nKibMf3nBZ #skcsm #skincancer #oncology #ASCO23 @BhatiaS_MD @FredHutch (@ASCOPost)

Catch Dr. @BhatiaS_MD's oral presentation this evening at #ASCO23 as he shares research findings from a Phase 2 clinical trial in metastatic #Merkelcellcarcinoma patients. See more highlights: https://t.co/2etNii6xoP (@fredhutch)

Non randomized study on nivo as well as ipi/nivo in IO naive pts with recurrent/metastatic Merkel cell carcinoma with similar ORR for both arms (60 and 58%) #RareCancers #RareDisease Presented by @BhatiaS_MD @UWMedicine #ASCO23 (@FunchainMD)

Today @ASCO 2023, @evanlipson presents 2-year follow-up data on a study of patients with untreated or unresectable #melanoma. Dr Suzanne Topalian & Dr William Scharfman will present the results of a trial for patients with advanced Merkel-cell carcinoma. https://t.co/69ZttsLfGK (@hopkinskimmel)

Thank you to @AndrewBrohl for stopping by to discuss results from a phase 1b trial of the novel personalized cancer vaccine IFx-Hu2.0 in ICI- resistant Merkel cell carcinoma and cutaneous squamous cell carcinoma! @ASCO #ASCO23 #ASCO2023 #oncology (@OncLive)

Moffitt's Dr. @AndrewBrohl discusses a phase 1b trial of IFx-Hu2.0, a novel personalized cancer vaccine, in checkpoint inhibitor resistant Merkel cell carcinoma and cutaneous squamous cell carcinoma while at #ASCO23. Learn more ➡️ https://t.co/bCfSUUHEIf #MoffittASCO23 @ASCO (@MoffittNews)

At low power, it has a nested pattern. One of my differentials include Merkel Cell Carcinoma. Stains: CK20, synaptophysin and chromagranin. (@debakeyforceps)

Excellent review by @jasonlukemd @UPMCHillmanCC of some key #immunotherapy #cancerimmunotherapy #IO abstracts #immunooncology #oncology #Cancer #cancers #melanoma #merkelcellcarcinoma #colorectalcancer #counterregulatoryantibodies #ASCO2023 #ASCO23 (@sejadiMD)

My dad was diagnosed with Merkel Cell Carcinoma last June. As of right now, he’s doing well after surgery and radiation. But Keytruda was considered. He elected not to add it in due to potential side effects and...cost. He’s privileged enough he’d be ok. Ish. But...yeah. (@wabbit89)

💡#MerkelCell #Cancer is a “neuroendocrine” tumor of the skin. Some series quote the rates as high as over 90%. Trials considering somatostatin analogues date back to 15 years and people have been talking about SSTR2 since the 90s! See this 1999 - 9/10➕ https://t.co/m3V7wUjzgS (@pashtoonkasi)

Excellent repurposing of existing #radiopharmaceuticals therapy agent for new indications! Do you have a sense for the % of Merkel Cell Carcinoma that expresses SSTR? (@freddyeescorcia)

Genomic Alterations and Tumor Mutation Burden in Merkel Cell Carcinoma https://t.co/unH3HMMUQ9 via @JAMANetworkOpen part of @JAMANetwork @jtmoyers (@VivekSubbiah)

Searching for rare cancers in the @AACR Genie database. Over 300 Merkel cell cancer NGS samples analyzed! Many likely to benefit from checkpoint and some to targeted therapies! Genomic Alterations and Tumor Mutation Burden in Merkel Cell Carcinoma https://t.co/yxotgNC1Fb (@jtmoyers)

New #JITC article: Transcriptional and functional analyses of neoantigen-specific CD4 T cells during a profound response to anti-PD-L1 in metastatic Merkel cell carcinoma https://t.co/wN63ZzHImN @robamezquita @raphg @jaehyukchoimd @PaulNghiem (@jitcancer)

Dr. Virginia ViLolsi taking us through a nice example of hyalinizing trabecular tumors of the thyroid. GLIS rearrangements define these lesions! #USCAP2022 @TheUSCAP (@missDoctorZ)

Combination #immunotherapy (CTLA4⛔️➕PD1⛔️) has been shown to salvage progression on single-agent PD1⛔️. 👇🏾Several reports of #melanoma @JCO_ASCO @ASCO. Also case series in #merkelcellcancer & other tumor types. Read @jitcancer our📝#ColorectalCancer. ➡️https://t.co/ZFOmTs521o (@pashtoonkasi)

hyalinizing trabecular tumor is GLIS rearrangement. #USCAP2021 (@Ranges91)

Its interesting that a subset of merkel cell carcinomas express both: PAX5 and TDT (@gonzadetoro)

#ASCO20: Targeting MDM2 in #merkelcellcarcinoma: https://t.co/ydbdSSOKID #skcsm #melsm #JNCCN360 (@JNCCN)

On #RareDiseaseDay we're highlighting #immunotherapy in rare cancers. PD1/L1 has transformed treatment for #Merkelcell carcinoma. Great work from @sitcancer leaders such as Dr. Kaufman @OmidHamidMD & international #MCC genius @paulxtn! https://t.co/cSYttxlxZ4 (@jitcancer)

PD1/L1 #Immunotherapy has changed the game across #skincancer but especially in #merkelcellcarcinoma! Definitive data updated from @sitcancer's Dr. Kaufman in #JITC: https://t.co/8pVF8wSqZ3 (@jitcancer)

Worth considering given presentation (typically CK20+, TTF1-). Occult primary #merkelcellcarcinoma (after thorough skin check) also ➡️ better prognosis https://t.co/ncadFEkzGn @JMGardnerMD (@dr_jonathant)